{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:08Z","timestamp":1791231548245,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous squamous cell carcinoma (cSCC) of the skin is the second most common form of skin cancer, with aging and prolonged exposure to ultraviolet rays being the main causes of the disease. Cemiplimab and pembrolizumab recently gained regulatory approval for the treatment of locally advanced and metastatic cSCC\u2014conditions that are not treatable by surgical resection and\/or radiotherapy. Although the results from the clinical trials have been promising, these studies have not included immunosuppressed, elderly patients. In this study, we included all immunocompromised and immunocompetent patients over the age of 75 years diagnosed with locally advanced or metastatic cSCC and treated with cemiplimab or pembrolizumab. The median duration of follow-up from cSCC diagnosis was 35.6 months, 82.9% of patients were male, and the median age was 83 years old. The median progression-free survival was 8.94 months. The incidence of treatment-related adverse events was 85.6%, the majority of which were grades 1 or 2. The disease control rate was 91.4%, the complete response rate was 17.1%, the partial response rate was 51.4%, the stable disease rate was 23%, and the progressive disease rate was 8.7%. Based on this study, cemiplimab and pembrolizumab for the treatment of locally advanced or metastatic cSCC in elderly, immunocompromised patients are efficacious, with acceptable safety profiles.<\/jats:p>","DOI":"10.3390\/cancers15164041","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T10:24:47Z","timestamp":1691663087000},"page":"4041","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Alexander","family":"Yakobson","sequence":"first","affiliation":[{"name":"The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Abu Jama","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, The Emek Medical Centre, Afula 18341, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Michlin","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-4550","authenticated-orcid":false,"given":"Walid","family":"Shalata","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"686308","DOI":"10.3389\/fonc.2021.686308","article-title":"Cemiplimab in an Elderly Frail Population of Patients with Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy","volume":"11","author":"Strippoli","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (Keratinocyte carcinomas) in the US population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_4","first-page":"6","article-title":"Update of advanced cutaneous squamous cell carcinoma","volume":"36","author":"Lammerts","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamadermatol.2015.4994","article-title":"Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death","volume":"152","author":"Thompson","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2","volume":"128","author":"Stratigos","year":"2020","journal-title":"Treatment. Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol. Surg."},{"key":"ref_8","first-page":"350","article-title":"HIV Infection Status, Immunodeficiency, and the Incidence of Non-Melanoma Skin Cancer","volume":"105","author":"Silverberg","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC)","volume":"39","author":"Jarkowski","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jgo.2014.12.002","article-title":"Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors","volume":"6","author":"Gajra","year":"2015","journal-title":"J. Geriatr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.6004\/jnccn.2021.0059","article-title":"NCCN Guidelines\u00ae Insights: Squamous Cell Skin Cancer, Version 1.2022","volume":"19","author":"Schmults","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e000775","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bjps.2018.03.019","article-title":"A 5-year follow-up study of 633 cutaneous SCC excisions: Rates of local recurrence and lymph node metastasis","volume":"71","author":"Khan","year":"2018","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2340\/00015555-2901","article-title":"Metastasis Risk of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients and Immunocompetent Patients","volume":"98","author":"Genders","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.012","article-title":"Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients","volume":"108","author":"Stoff","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.03.004","article-title":"Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma","volume":"113","author":"Kacew","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S737","DOI":"10.1016\/j.annonc.2020.08.1210","article-title":"1086P Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience","volume":"31","author":"Hober","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"625872","DOI":"10.3389\/fonc.2021.625872","article-title":"The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/cncr.20976","article-title":"The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma","volume":"103","author":"Hashimoto","year":"2005","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14474","DOI":"10.1038\/s41598-017-13934-8","article-title":"Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma\u2014A multicenter study","volume":"7","author":"Bekos","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14740\/wjon1084w","article-title":"Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma without Driver Mutation","volume":"9","author":"Minami","year":"2018","journal-title":"World J. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3389\/fonc.2019.00995","article-title":"Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study","volume":"9","author":"Wang","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"642380","DOI":"10.3389\/fmed.2021.642380","article-title":"Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects","volume":"8","author":"Deacon","year":"2021","journal-title":"Front. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e000897","DOI":"10.1136\/jitc-2020-000897","article-title":"Original research: Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: A retrospective multicenter DeCOG study of 84 patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_37","unstructured":"Chapman, J.R., Webster, A.C., and Wong, G. (2023, May 01). Cancer in the Transplant Recipient. Available online: http:\/\/perspectivesinmedicine.cshlp.org\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: A meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wright, Q., Cruz, J.L.G., Wells, J.W., and Leggatt, G.R. (2021). PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy. Cancers, 13.","DOI":"10.3390\/cancers13133310"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-020-02558-z","article-title":"PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1\/PD-L1 blockade","volume":"69","author":"Trefny","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pesce, S., Trabanelli, S., Di Vito, C., Greppi, M., Obino, V., Guolo, F., Minetto, P., Bozzo, M., Calvi, M., and Zaghi, E. (2020). Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. Cancers, 12.","DOI":"10.3390\/cancers12123504"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1537581","DOI":"10.1080\/2162402X.2018.1537581","article-title":"Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients","volume":"8","author":"Lee","year":"2019","journal-title":"Oncoimmunology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:30:04Z","timestamp":1760128204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":42,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15164041"],"URL":"https:\/\/doi.org\/10.3390\/cancers15164041","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}